Evaxion Biotech A/S (NASDAQ:EVAX) Sees Significant Growth in Short Interest

Evaxion Biotech A/S (NASDAQ:EVAX) was the target of a large growth in short interest in August. As of August 15th, there was short interest totalling 45,400 shares, a growth of 9.4% from the July 31st total of 41,500 shares. Based on an average trading volume of 42,700 shares, the days-to-cover ratio is currently 1.1 days.

Institutional Investors Weigh In On Evaxion Biotech A/S

Institutional investors and hedge funds have recently modified their holdings of the company. Invst LLC purchased a new position in shares of Evaxion Biotech A/S during the second quarter worth $156,000. LM Advisors LLC acquired a new stake in Evaxion Biotech A/S during the 4th quarter worth about $231,000. Finally, Armistice Capital LLC raised its stake in shares of Evaxion Biotech A/S by 6.8% during the 2nd quarter. Armistice Capital LLC now owns 392,000 shares of the company’s stock valued at $1,137,000 after buying an additional 25,000 shares during the last quarter. Institutional investors and hedge funds own 11.04% of the company’s stock.

Evaxion Biotech A/S Stock Up 3.6 %

NASDAQ EVAX traded up $0.11 during trading on Tuesday, hitting $3.16. The company’s stock had a trading volume of 19,396 shares, compared to its average volume of 273,295. Evaxion Biotech A/S has a fifty-two week low of $2.26 and a fifty-two week high of $13.61. The company has a market cap of $17.10 million, a PE ratio of -0.72 and a beta of -0.28. The company has a debt-to-equity ratio of 7.99, a current ratio of 2.80 and a quick ratio of 2.80. The business’s 50 day simple moving average is $2.96 and its 200-day simple moving average is $3.36.

Evaxion Biotech A/S (NASDAQ:EVAX) last posted its quarterly earnings results on Wednesday, August 14th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.14). The business had revenue of $0.15 million for the quarter, compared to analyst estimates of $0.10 million. During the same period in the prior year, the company posted ($2.10) earnings per share. On average, equities analysts anticipate that Evaxion Biotech A/S will post -0.24 EPS for the current fiscal year.

Analysts Set New Price Targets

Separately, HC Wainwright restated a “buy” rating and set a $14.00 price objective on shares of Evaxion Biotech A/S in a research note on Friday, August 16th.

Evaxion Biotech A/S Company Profile

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase 1/2a trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy that is in pre-clinical stage for the treatment of various cancers.